J2Kbio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
J2Kbio makes ingredients used in cosmetics, the raw materials that go into skincare, functional beauty, colour cosmetics, hair, and body-care products.
It supplies these ingredients to cosmetics manufacturers and also provides clinical testing services, evaluating the efficacy of cosmetics, health-functional foods, and beauty devices on behalf of clients. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: cosmetic ingredient manufacturing and a clinical-services unit run through a subsidiary.
Summary is AI-generated and may contain errors · figures from DART filings
The clinical-services business is operated through a separately established subsidiary, giving the group a vertically integrated offering from ingredient supply to efficacy testing.
J2Kbio in five facts
What does J2Kbio do?
J2Kbio makes ingredients used in cosmetics, the raw materials that go into skincare, functional beauty, colour cosmetics, hair, and body-care products.
Where is J2Kbio listed and in which sector?
J2Kbio (Korean name: 제이투케이바이오) trades under KRX code 420570 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is J2Kbio?
Its market capitalisation was US$38.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were J2Kbio's latest annual revenue and operating profit?
For fiscal year 2025, J2Kbio reported revenue of US$24.9M, operating profit of US$2.2M and net income of US$2M, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was down 0.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
J2Kbio declared a cash dividend of US$0.17 per share.
Dividend · Feb 12 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
J2Kbio reported consolidated results for FY2025: revenue of US$22.8M (−0.5% year on year), operating profit of US$2.02M (−19.5% year on year) and net income of US$1.82M (from a loss a year earlier).
Earnings · Feb 12